dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Kiri

Sotsiaalministeerium · 25. veebruar 2020
Viit
1.4-2/446-2
Registreeritud
25. veebruar 2020
Dokumendi liik
Sissetulev kiri
Adressaat
National Health Commission, China
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Kärt Sõber (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Rahvatervise osakond)

Failid

  • 📎E-kiri.pdf310 KB
  • 📎eng clinical protocol.pdf420 KB
  • 📎eng 9 Prevention and control protocols for specific groups and settings v1.pdf298 KB
  • 📎eng Annex 1 case surveillance v4.pdf237 KB
  • 📎eng Annex 3 close contact v4.pdf472 KB
  • 📎eng prevention and control protocol v4.pdf356 KB

Sisu (failidest)

Annex 1 Protocol for Novel Coronavirus Pneumonia Case Surveillance (fourth Version) Since December 2019, novel coronavirus pneumonia cases have been detected in Wuhan City, Hubei Province. This Protocol is formulated to provide guidance on timely detection and reporting of novel coronavirus pneumonia cases in local efforts so as to ensure early detection and early reporting and prevent the spread of the epidemic. I. Purpose 1) To timely detect and report the novel coronavirus pneumonia cases, infected persons and clusters of cases; 2) To understand the characteristics of the epidemic situation of novel coronavirus infections in the country so as to assess in a timely manner the epidemic trend. II. Surveillance case definition Provinces outside Hubei A. Suspect cases Make comprehensive analysis based on the following epidemiological history and clinical manifestations: 1.Epidemiological history 1) Travel or residence history in Wuhan and its surrounding areas or other communities with reported cases within 14 days before the onset of the disease; 2) History of contact with novel coronavirus infected patients (whose were tested positive for nucleic acid) within 14 days before the onset of the disease; 3) Having contact with patients with fever and respiratory symptoms who are from Wuhan and its surrounding areas or other communities with reported cases within 14 days before the onset of the disease; 4) Part of a cluster of cases. 2. Clinical manifestations: 1) Fever and/or respiratory symptoms; 2) Radiological findings of pneumonia; 3) Normal or lower WBC count, or lower lymphocyte count in early stage. Cases that meet any one of the epidemiological history and any two of the clinical manifestations, or have all three clinical manifestations if there is no clear epidemiological history, are defined as suspect cases. B. Confirmed case Confirmed case are suspect case with one of the following etiological evidences: 1. Respiratory specimens or blood specimens found nCoV nucleic acid positive on RT- PCR; 2. Virus gene sequencing of respiratory or blood samples is highly homologous with the known novel coronavirus. C. Asymptomatic infected persons Individuals without clinical symptoms but whose respiratory and other specimens are tested positive for the novel coronavirus. They are mainly detected through investigation of clusters of cases and tracking investigation of the infection source. D. Clusters of cases Clusters of cases refer to two and more confirmed cases or asymptomatic infected persons detected in a small group such as a family, a construction site or a workplace within 14 days, with the possibility of human to human transmission due to close contacts or common exposure. Hubei Province A. Suspect cases Make comprehensive analysis based on the following epidemiological history and clinical manifestations: 1.Epidemiological history 1) Travel or residence history in Wuhan and its surrounding areas or other communities with reported cases within 14 days before the onset of the disease; 2) History of contact with novel coronavirus infected patients (whose were tested positive for nucleic acid) within 14 days before the onset of the disease; 3) Having contact with patients with fever and respiratory symptoms who are from Wuhan and its surrounding areas or other communities with reported cases within 14 days before the onset of the disease; 4) Part of a cluster of cases. 2. Clinical manifestations 1) Fever and/or respiratory symptoms; 2) Normal or lower WBC count, or lower lymphocyte count in early stage. Cases that meet any one of the epidemiological history or have both clinical manifestations if there is no epidemiological history, are defined as suspect cases. B. Clinically diagnosed cases They are suspect cases with radiological findings of pneumonia. C. Confirmed case They are clinical diagnosed cases or suspect cases with one of the following etiological evidences: 1. Respiratory specimens or blood specimens found nCoV nucleic acid positive on RT- PCR; 2. Virus gene sequencing of respiratory or blood samples is highly homologous with the known novel coronavirus. D. Asymptomatic infected persons Individuals without clinical symptoms but whose respiratory and other specimens are tested positive for the novel coronavirus. They are mainly detected through investigation of clusters of cases and tracking investigation of the infection source. E. Clusters of cases Clusters of cases refer to two and more confirmed cases or asymptomatic infected persons detected in a small group such as a family, a construction site or a workplace within 14 days, with the possibility of human to human transmission due to close contacts or common exposure. III. Work Content 1. Case detection 1) Healthcare facilities at all levels should raise their awareness of diagnosis and reporting of novel coronavirus pneumonia cases. Patients with symptoms like fever, cough, shortness of breath etc. of unknown causes should be asked about any history of travel to or residence in Wuhan or surrounding areas or other communities with cases reported, whether they have exposure to patients with fever or respiratory symptoms in the above areas or communities, whether they are part of a cluster of cases or have been in contact with any novel coronavirus infected persons within 14 days before onset of the disease. 2) Relevant grassroots organizations should screen those who have travel or residence history in Wuhan or surrounding areas or communities with cases reported, who have respiratory symptoms, fever, chills, fatigue, diarrhea, conjunctival congestion etc. within the past 14 days as high-risk persons, and have their specimens collected and tested by professional institutions. 2. Case reporting When healthcare facilities at all levels and of all kinds detect suspect cases, clinically diagnosed cases (only for Hubei Province), confirmed cases and asymptomatic infection cases, they should report via the direct online reporting network within 2 hours. The address box in the infectious disease report card should be filled with the place of residence at the time of disease onset, and detailed to the village, residence group, community, household number etc. so that the case can be traced. The CDC should investigate and verify immediately after receiving the report and complete the three-level review and confirmation of the reported information through the network within 2 hours. Healthcare facilities that do not have the capacity of direct online reporting should immediately report to the local county/district CDC and send out the completed infectious disease reporting card within 2 hours. The county/district CDC, upon receiving the report, should immediately make a direct online reporting and any subsequent revision of the information. When reporting cases online, select "novel coronavirus pneumonia" for the type of disease, and report as a “suspect case", "clinically diagnosed case (in Hubei Province only)”, “confirmed case” or “tested positive” for case classification. “Clinical severity” of suspect cases, clinically diagnosed cases (in Hubei Province only) and confirmed cases should be classified and reported as “mild”, “moderate”, “severe” or “critical” in accordance with the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Fifth Version). “Tested positive” specifically refers to asymptomatic infected persons, and its clinical severity is "asymptomatic infected person". The reported "suspect cases" and "clinical diagnosed cases (in Hubei Province only)” should be promptly corrected to "confirmed cases" or eliminated in accordance with the laboratory test results. If the reported "asymptomatic infected persons" have clinical manifestations, they shall be corrected timely as "confirmed cases". "Clinical severity" of all cases shall be timely amended according to the disease progression, with the most severe state of the case as its final state. 3. Detection and reporting of incidents According to the requirements of the National Public Health Emergency Response Contingency Plan and the National Public Health Emergency Related Information Reporting and Management Rules (Trial), the index novel coronavirus pneumonia confirmed case or cluster in the county/district should be reported within two hours by the local CDC in the jurisdiction through online direct reporting system for public health emergencies. The incident level can be categorized as "unclassified" for the time being. The health authority shall classify the incident level based on investigation findings, subsequent progress, and results of risk assessment, and adjust it in the system, and submit the initial report, progress report and final report online in a timely manner. 4. Epidemiological investigation The county/district CDC upon receiving reports of suspect cases, clinically diagnosed cases (in Hubei Province only), confirmed cases and asymptomatic infected persons, should complete case investigation within 24 hours, and register the close contacts in a timely manner. For details, please refer to the Epidemiological Investigation Protocol for Novel Coronavirus Pneumonia Cases (Fourth Version) and the Protocol for Management of Close Contacts of Novel Coronavirus Pneumonia Cases (Fourth Version). After completing the case investigation, the county/district CDC should submit the case investigation information of confirmed cases and asymptomatic infected persons through the online direct reporting system in a timely manner. The county/district CDC should submit the epidemiological investigation and analysis report to the health authority at the same level and the CDC at a higher level in time. 5. Specimen collection and laboratory testing Healthcare facilities that admit and treat suspect cases, clinically diagnosed cases (for Hubei Province only) and clusters of cases should collect relevant clinical specimens of the cases and send the specimens to the designated local CDC, healthcare facilities or third- party testing institutions as soon as possible for related pathogenic testing. The collected clinical specimens include patients' upper respiratory tract specimens (such as throat swabs, nasal swabs, etc.), lower respiratory tract specimens (such as deep cough sputum, respiratory tract extracts, bronchial lavage fluid, pulmonary alveoli lavage fluid, etc.), eye conjunctiva swabs, stool specimens, anticoagulant and serum specimens etc. Efforts should be made to try to collect respiratory tract specimens (especially lower respiratory tract specimens) early in the onset of the disease, serum in the acute stage within 7 days of onset and convalescence serum in the third to fourth week after onset. Specific requirements for clinical specimen collection and laboratory testing are described in the Technical Protocol for Laboratory Testing of Novel Coronavirus Pneumonia (Fourth Version). Specimen collection, transportation, storage and testing are temporarily managed as level 2 highly pathogenic microorganisms, in accordance with the Regulations on Biological Safety Management of Pathogenic Microbial Laboratories, the Regulations on the Management of Transportation of Highly Pathogenic Microorganisms or Samples that Can Infect Humans (Ministry of Health Order No. 45) and other related requirements. 6. Requirements for verification of laboratory test results of clusters of cases The original specimens of clusters of five or more novel coronavirus pneumonia cases in each region should be sent to the Chinese Center for Disease Control and Prevention for verification and confirmation. Annex 3 Protocol for Management of Close Contacts of Novel Coronavirus Pneumonia Cases (Forth Version) This Protocol was formulated to identify and manage close contacts of Novel Coronavirus Pneumonia Cases and effectively control the spread of the disease, based on the current understanding of novel coronavirus pneumonia, the incubation period being up to 14 days and human-to-human transmission in existence. I. Definition Close contacts refer to people who have any of the following unprotected contacts with suspect cases, clinically diagnosed cases (Hubei Province only) and confirmed cases after their onset, or with asymptomatic infected people who are tested positive: 1. Those living, studying, working or other close contacts such as working in close distance, or sharing the same classroom or living in the same room; 2. Health care workers or family members who diagnose, treat, take care of or visit the case, or other people who have similar close contact with the case, such as those directly treating and nursing the case, visiting the case or staying in the closed environment where the case stays, roommates of the case and their carers in the same room; 3. People who are in the same transportation with the case and have close contacts, including those who have taken care of the patient on the transportation, accompanying people of the patient (family, colleagues, friends, etc.), or other passengers and crew members assessed by investigation as having close contacts with cases or asymptomatic infected persons. See Appendix 1 for methods to assess close contacts in different transportations. 4. Those assessed by field investigators as meeting criteria of close contacts. The identified close contacts should be entered into the Registration Form for Close 1 Contacts of Novel coronavirus Pneumonia Cases (see Appendix 2). II. Requirements in management (I) Management of close contacts. This is arranged by local health authorities along with relevant departments. For those who rejects medical observation, the local public security agency may involve and take them into mandatory isolation. 1. When individuals are put under medical observation, they should receive verbal or written notification on the justification, duration, legal basis, issues to note, knowledge of the disease, name and phone number of contact person and the health care facility that are responsible for the medical observation. 2. Medical observation can take place in centralized settings. If not feasible, this can take place at home with closer management of the contacts. The medical observation period is 14 days after the last unprotected contact with the case or asymptomatic infected person. The close contacts of a confirmed case or asymptomatic infected person should complete the 14-day quarantine even if they are tested negative during quarantine. If a suspect case is cleared, the medical observation of his or her close contacts is thus terminated. 3. Persons under centralized or home-based medical observation should live relatively independently to minimize contact with co-residents. Adequate cleaning and disinfection are done to the observation sites to minimize contamination per Technical Protocol for Disinfecting Specific Locations (2nd Edition). They should not go out during the observation period. If going out is necessary, approval from the medical observation management personnel has to be obtained. When going out, the person should wear a disposable surgical mask and avoid going to crowded places. 4. General contacts (other than close contacts with whom a case has lived, studied or worked with) who were not in the same plane, train, ferry or other transportation vehicle with the case should be provided with information on the health risks, the necessity of seeking medical attention whenever fever, coughing or other respiratory symptom, diarrhea, 2 or conjunctival suffusion develops, and the obligation to provide history of recent activities. (II) Measures taken during medical observation 1. During medical observation, measures to be taken are: (1) During the medical observation, a designated health facility staff shall take the person’s temperature in the morning and evening every day, ask about the person’s health status, fill in the medical observation record form, provide necessary help and guidance and fill in the Medical Observation Registration Form for Close Contacts of Novel coronavirus Pneumonia Cases (Appendix 3). The Daily Report Form for Medical Observation of Close Contacts of Novel coronavirus Pneumonia Cases (Appendix 4) and Daily Summary Form for Medical Observations of Close Contacts of Novel coronavirus Pneumonia Cases (Appendix 5) can be references for local staff to use when consolidating the data. (2) The medical observation manager should take precautions in personal protection per Precaution Protocol for Specific Populations (2nd Edition). 2. During the medical observation, if the person under observation develops any symptoms (including fever, chill, dry cough, productive cough, nasal congestion, rhinorrhea, sore throat, headache, weakness, myalgia, joint soreness, shortness of breath, dyspnea, chest distress, conjunctival suffusion, nausea, vomiting, diarrhea and abdominal pain), it should be reported immediately to the local health authority, and the person should be transferred to a designated health care facility according to regulations for diagnosis and treatment with specimen collected for laboratory testing and screening. If the person is identified as a suspect case, confirmed care or clinically diagnosed case (for Hubei Province only), the close contacts should be put under medical observation. 3. Upon the completion of medical observation, if the close contact has no presentation of any abnormalities, he or she should be lifted from the medical observation. (III) Locations for centralized medical observation 1. The following criteria should be met in selecting and equipping the premises for centralized medical observation: 3 (1) Centralized medical observation facilities should be located in a downwind, relatively isolated area with easy access to transportation system. It should also be away from densely populated areas (at least 500 meters away in principle). It should not be located in a health care facility. (2) Within the facilities for centralized observation, there should be different functional areas with clear signs such as living areas, supply areas and patient-care areas. The premise should be properly ventilated, equipped with basic facilities to support normal living of people under medical observation and easy for implementing regular disinfection measures. (3) The premise should have its own septic tank. Sewage should be disinfected before discharged into the municipal sewage network by treated regularly with chloride agent. The treated sewage should contain 10 mg/L chloride residue 1.5 hours after the administration of chloride agent and meet Sewage Discharge Standards for Health Care Facilities (GB18466-2005). An alternative to stand-alone septic tank is a container exclusive for excrement collection. It is disposed of only after being disinfected and treated per General Disinfection Guideline for Epidemic Area (GB19193-2015). 2. Single rooms should be available in the centralized observation premise to accommodate individuals with respiratory symptoms (fever and cough), diarrhea, conjunctival suffusion, etc. Their specimens should then be taken for screening testing. Appendixes 1. Guidance on assessment of close contacts in transportation system 2. Registration Form for Close Contacts of Novel coronavirus Pneumonia Cases 3. Medical Observation Daily Registration Form for Close Contacts of Novel coronavirus Pneumonia Cases 4. Daily Report Form for Medical Observation of Closely Contacts of Novel coronavirus Pneumonia Cases 4 5. Daily Summary Form for Medical Observations of Close Contacts of Novel coronavirus Pneumonia Cases 5 Appendix 1 Guidance on assessment of close contacts in transportation system 1. Airplane (1) Close contacts are defined as those seated in the same row, within three rows in the front and three rows in the back of the patient as well as the crew members serving the defined areas in the aircraft. Other passengers are grouped as general contacts. (2) The definition expands to everyone in the aircraft if it is not equipped with high-efficiency particulate filter. (3) Other known close contacts of the case. 2. Train (1) For closed and air-conditioned train, close contacts are all the passengers and crew members who were in the same car of hard seat or hard sleeper, or in the same compartment of soft sleeper with the patient. (2) For regular train other than the closed one, passengers in the same compartment of soft sleeper, or the same segment and the next segments both back and front in the same car of hard seat or hard sleeper as the patient, and the crew members assigned to these areas are close contacts. (3) Other known close contacts of the case. 3. Coach (1) For a closed and air-conditioned coach, all the passengers in the same coach are close contacts. (2) For a regular coach other than a closed one, passengers in three rows in the front and three rows in the back as well as the driver are close contacts. (3) Other known close contacts of the case. 6 4. Ferry All the passengers in the same cabin as the patient as well as the crew members assigned to this area. During the contact period, if the passenger already had obvious symptoms like fever, sneezing, coughing or vomiting, he or she should be classified as a close contact regardless of the duration of the contact. 7 Appendix 2 Registration Form for Close Contacts of Novel coronavirus Pneumonia Cases Relation First Last Notes Contact Contact Contact Ways of Name Gender Age with contact contact (duration of No. patient time time frequency place contact each contact) 1. Contact frequency: ① often ② average ③ occasionally 2. Contact place: ① At home ② Healthcare facility ③ Workplace ④ Entertainment setting ⑤ Other (please specify) 3. Ways of contact: ① Eat together ② Share apartment ③ Share room ④ Share bed ⑤ Work and study in the same room ⑥ Diagnosis and treatment ⑦ In the same ward ⑧ Entertainment activities ⑨ Other (please specify) 8 Appendix 3 Medical Observation Daily Registration Form for Close Contacts of Novel coronavirus Pneumonia Cases □ suspected □ confirmed name: contact number: date of onset: Clinical manifestation Observation No. Name Gender Age Address Temperature (℃) Cough Short of breath started (date) 1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7 Note: 1. This table is to be used by health personnel who are observing the close contacts of novel coronavirus pneumonia cases. 2. Tick √ when there are “cough" and "short of breath" or × when there is no such symptoms. Organization: Name: Date: (year/ month/ day) 9 Appendix 4 Daily Report Form for Medical Observation of Closely Contacts of Novel coronavirus Pneumonia Cases People under medical observation Number of people developing clinical Conversions Expected Street / Date when Cumulative Observation # of discharge manifestations date when Commu observation number of s on the day the last close nity or for the first people To contact is Home case started observed To # New Pending Total New Total asymptomat Total discharged patient ic contact Total - Note: 1. This form is used by health care workers for consolidating data for reporting. 2. Clinical manifestations: fever, cough, shortness of breath, etc. 3. The cumulative numbers in the table refer to the aggregated numbers since the medical observation starts. Organization: (health care facility) Name: Date: (year/ month/ day) 1 Appendix 5 Daily Summary Form for Medical Observations of Close Contacts of Novel coronavirus Pneumonia Cases People under medical observation Number of people developing clinical Conversions Expected Date when Cumulative Observation # of discharge manifestations date when Catchme observation number of s on the day the last close nt for the first people To contact is case started observed To # New Pending Total New Total asymptomat Total discharged patient ic contact Total - Note: 1. This table can be used by city and district CDCs for statistical summary. 2. Clinical manifestations: fever, cough, shortness of breath, etc. 3. The cumulative numbers in the table refer to the aggregated numbers since the medical observation started. Organization: CDC Name: Date: (year/ month/day) 11 12 Novel Coronavirus Infection Control Protocol (Edition 4) Novel coronavirus belongs to β-type coronavirus and its genetic characteristics are significantly different from SARSr-CoV and MERSr-CoV. The virus is sensitive to ultraviolet rays and heat. It can be killed by heating for a time period of 30 minutes at 56°C and lipid solvents such as ether, 75% ethanol, chlorine-containing disinfectant, peracetic acid and chloroform can also effectively inactivate the virus. Based on current epidemiological survey and research results, the incubation period is 1-14 days, mostly 3-7 days. The source of infection is mainly patients infected by novel coronavirus and asymptomatic infected persons may also become source of infection. Main transmission routes are droplet transmission and contact transmission. Whether there exist aerosol and fecal-oral transmission still needs further investigation. All population is susceptible. This Protocol is an update on the 3rd Edition of Novel Coronavirus Pneumonia Prevention and Control Protocol based on the policy that novel coronavirus pneumonia is classified as a category- B infectious disease but regulated as a category-A infectious disease, current epidemic situation across China and the latest findings in case epidemiology and clinical researches, in order to prevent and control the spread of novel coronavirus, strengthen the organization and coordination of prevention and control relevant institutions, improve the epidemic information surveillance and reporting to achieve the goal of "early detection, early reporting, early diagnosis, early isolation, and early treatment", reduce mortality rate, protect people’s safety and health and maintain social stability. I. Purposes Timely detect and report pneumonia cases caused by novel coronavirus, understand the disease characteristics and exposure history, standardize close contact management, instruct the public and specific groups on how to well protect themselves, strictly disinfect specific places, effectively curb the spread in community and reduce the harm caused by novel coronavirus to public health. II. Scope of application It is applicable to guide prevention and control work in various places. This Protocol will be updated in a timely manner based on the changes in the epidemic situation and the assessment results. III. Prevention and control measures 1. Improve prevention and control mechanism and strengthen organizational leadership. Great importance should be attached to the prevention and control of pneumonia outbreaks caused by the new coronavirus. Under the leadership of the government at the corresponding level, the health authorities at all levels should strengthen their guidance on the prevention and control of epidemics, establish technical expert groups, organize the relevant departments to formulate and improve relevant work and technical protocols in accordance with the principles of “prevention first, integration of prevention and treatment, scientific guidance, and timely treatment” so as to standardize the prevention and control measures against the pneumonia outbreak caused by the new coronavirus. Strengthen joint prevention and control as well as information communication and interaction of measures between departments, regularly discuss and determine the development trend of the epidemic and agree on prevention and control policies. The health authorities at all levels are responsible for the overall guidance of epidemic control and ensuring the funds and supplies are in place. CDCs at all levels are responsible for organizing, coordinating, supervising and evaluating surveillance work, collecting, analyzing, reporting and feedbacking surveillance data; conducting field investigations, laboratory testing and technical training; conducting public health education and risk communication. CDCs at all levels should also guide the public and specific groups to well protect themselves and direct the disinfection work of specific place. Healthcare facilities at all levels are responsible for case finding and reporting, isolation, diagnosis, treatment and clinical management, collecting specimens and providing training for healthcare workers to curb nosocomial infection. 2. Case and emergence detection and reporting. Health care facilities and CDCs at all levels and of all types should conduct surveillance, detection and reporting of pneumonia cases (including asymptomatic infected persons ) due to novel coronavirus in accordance with the Novel coronavirus pneumonia case surveillance protocol (4th Edition) (see Annex 1). 1) Case detection. Health care facilities at various levels should be alerted when doing case diagnosis and reporting in the process of daily monitoring and treatment. For cases with fever and cough caused by unknown reasons, travel history or suspicious exposure history within 14 days before the onset of illness should be consulted, whether patients went to the city of Wuhan or its surrounding areas, whether patients traveled to or resided in a novel coronavirus outbreak community, or whether patients contacted with other who had fever and cough in the abovementioned areas or community, whether there exists the possibility of cluster caused illness or whether patients contacted with confirmed cases. Primary level organizations should put more efforts on screening people who travelled to or resided in Wuhan and its surrounding areas within recent 14 days, people who travelled to or resided in communities where confirmed cases have been reported and people who have respiratory symptoms, fever, chills, fatigue, diarrhea, conjunctival congestion and so forth. These people are key risk groups for screening. Their sampling and testing should be performed by professional institutions. 2) Case reporting. When Suspect cases, clinically diagnosed cases (for Hubei Province only), confirmed cases and asymptomatic cases of novel coronavirus pneumonia are detected, healthcare facilities should report cases immediately via online reporting system. Those without such capacity should make a prompt report to local county/district CDC and send out the notifiable disease reporting cards within 2 hours. Local county/district CDCs should make direct online report upon receiving the notification. According to Novel coronavirus pneumonia case surveillance protocol (4th edition), healthcare facilities or CDCs which are responsible for case reporting shall make corrections to information such as case classification and clinical severity in a timely manner based on laboratory test results and progress of disease. 3) Detection and reporting of emergencies Index novel coronavirus pneumonia case in each county/district and case clusters meeting the case definition of clustered cases set out in the Protocol of Novel Coronavirus Pneumonia Case Surveillance (4th Edition) should be reported online by the local CDC within 2 hours through the public health emergency reporting system with the severity level temporarily classified as “unclassified”. The severity level of the emergency shall be adjusted by the health authority adjust the later based on the investigation and follow up findings after the risk assessment done. 3. Epidemiological investigation. County/district CDCs upon receiving reports of Suspect cases, clinically diagnosed cases (for Hubei Province only), confirmed cases, asymptomatic cases and cluster epidemic from healthcare facilities or health care workers in their jurisdiction should conduct investigation according to the Protocol of Epidemiological Investigation of Novel Coronavirus Pneumonia (Fourth Edition) (See Annex 2) with 24 hours. County/district CDCs shall submit individual case investigation forms to superior institutions via infectious disease online reporting information system within 2 hours after completing case investigation of confirmed cases and asymptomatic infection. At the same time, epidemiological investigation analysis reports should also be submitted to health administrative department of the county/district and disease control agency of higher level. 4. Specimen collection and testing. Healthcare institutions receiving patients should collect relevant clinical specimens and send the specimens to local designated CDCs, medical facilities or third-party laboratories of testing institutions as soon as possible to carry out relevant pathogen detection (see Annex 4 for lab testing protocol). The clinical specimens include patient’s specimens from the upper respiratory tract (such as throat swabs, nasal swabs, etc.), lower respiratory tract (such as deep cough sputum, respiratory tract extracts, bronchial lavage fluid, alveolar lavage fluid, etc.), anticoagulation blood and serum specimens. Clinical specimens should preferably be respiratory specimens (especially from the lower respiratory tract) collected in early stage of the case, serum in the acute phase within 7 days after onset, and convalescent phase serum 3-4 weeks after the onset of disease. Specimen collection, transportation, storage and testing are temporarily managed per the protocols for Class II highly pathogenic microorganisms, in accordance with the Regulations on Biological Safety Management of Pathogenic Microbial Laboratories and Regulations on Transportation Management of Highly Pathogenic Microorganisms or Samples Infective to Humans (MoH Order No. 45) and other relevant requirements. 5. Case management and nosocomial infection prevention and control. Cases should be admitted for treatment to designated healthcare facilities where personnel, medicines, facilities, equipment and protective supplies required for medical treatment should be ensured. Healthcare facilities shall attach great importance to and strengthen the work of isolation, disinfection and protection according to the requirements of the Technical Guidelines for Novel Coronavirus Infection Control and Prevention in Healthcare Facilities (1st Edition), fully implement nosocomial infection control and prevention measures, improve triage of patients, and strengthen infection control and prevention in fever clinics, emergency rooms and all other general wards (rooms). Suspect cases, clinically diagnosed cases (for Hubei Province only) and confirmed cases should be isolated and treated at designated hospitals with effective isolation and protection conditions. Suspect cases and clinically diagnosed cases (for Hubei Province only) should be isolated in single rooms. Asymptomatic infected persons should be isolated collectively for 14 days, or they can be released after a 7-day isolation if nucleic acid test result shows negative. Healthcare facilities shall strictly clean and disinfect medical equipment, contaminated articles, surfaces and floors, etc. in accordance with the Technical Guidelines for Disinfection in Healthcare Facilities; perform air disinfection in accordance with the requirements of the Hospital Air Purification Management Regulations. Medical waste generated during the diagnosis and treatment of patients with new coronavirus pneumonia should be disposed of and managed in accordance with the relevant provisions in the Medical Waste Disposal Regulations and the Measures for Medical Waste Management in Healthcare Facilities. 6. Close contact tracking and management. Close contact tracing and management should be carried out by county/district health authorities in conjunction with relevant authorities. Closed contacts of suspect cases, clinically diagnosed cases (for Hubei Province only), confirmed cases and asymptomatic infected persons should go under medical observation in collective isolation. Where not feasible, they can be home quarantined (see Novel coronavirus pneumonia case close contact management protocol (Version 4) in Annex 3) and their body temperature should be taken at least twice a day and they should be asked about whether they have any acute respiratory symptoms or other relevant symptoms or disease progress. The medical observation should last for 14 days after the last contact with the case or asymptomatic infected person. 7. Public education and risk communication. Actively carry out public opinion monitoring, disseminate knowledge on epidemic prevention and control, promptly respond to concerns and questions of the public and conduct risk communicating in relation to epidemic prevention and control. Health education and risk communication shall be enhanced for key populations, settings and mass gathering events. In particular, guide the public and specific groups of personal protection through a variety of ways to reduce possible contact or exposure (see Personal protection guidelines for certain populations (Version 2) in Annex 5). At different stages of epidemic development, health education strategies should be adjusted timely by analysing psychological changes of the public and key information, and corresponding scientific public education should also be timely organized. Teachers, students and migrant workers returning back to work should be well informed with health tips and health management methods. 8. Strengthen training of health professionals in health and medical facilities. Provide training to health professionals in medical and health facilities on new coronavirus pneumonia case detection and reporting, epidemiological investigation, specimen collection, laboratory testing, medical treatment, infection control and prevention, close contact management and personal protection in order to improve capacities in prevention and control as well as diagnosis and treatment. 9. Strengthen laboratory testing capacity and raise awareness of biosafety and protection. Provincial CDCs, prefecture CDCs with laboratory testing capacity, and the designated health care facilities or the third-party testing agency should formulate laboratory diagnostic methods and have reagent and technology reserve and stand ready for lab testing at any time in accordance with laboratory biosafety regulations. 10. Timely disinfection of certain settings. Specific places such as residences of patients and asymptomatic infected persons , isolation wards in medical institutions, transfer vehicles and rooms where medical observation takes place should be disinfected in a timely manner. If needed, disinfection effects of object surfaces, air and hands should be evaluated timely as well (see Annex 6 ---Technical Protocols for Disinfection in Certain Places (second edition)). 11. Strengthen prevention and control measures targeting at key settings, institutions and populations. Strengthen the multi-sectoral joint prevention and control mechanism to minimize public gathering activities, and implement measures such as ventilation, disinfection and temperature taking in places with large population flow such as train stations, airports, ports, shopping malls, and closed vehicles such as cars, trains, and airplanes. Strengthen the prevention and control work of collectively living units such as schools and child care institutions, to perform morning inspection and absence registration due to illness. Strengthen the prevention and control work in cities with large numbers of migrants and make preparations for the doubled pressure on prevention and control work due to migrants after the end of Spring Festival. Strengthen health education for rural migrant workers, students and business personnel who return home. 12. Categorized community prevention and control. Different prevention and control strategies should be adopted for communities with different epidemic situations. For communities where no cases are reported, the strategy of "defense the external importation cases" should be implemented. For communities where there are cases or outbreaks, the strategy should be "preventing internal spread and importation from outside”. For more information, please refer to "Protocol of Community Prevention and Control of Novel Coronavirus Pneumonia (Trial)” released in the Notice on Strengthening Community Prevention and Control of Novel Coronavirus Pneumonia” (Pneumonia Mechanism [2020] No. 5). Annexes: 1. Novel coronavirus pneumonia case surveillance protocol (Version 4) 2. Novel coronavirus pneumonia epi investigation protocol (Version 4) 3. Novel coronavirus pneumonia case close contact management protocol (Version 4) 4. Novel coronavirus pneumonia lab technical guidelines (Version 4) 5. Personal protection guidelines for certain populations (Version 2) 6. Technical protocols for disinfection in certain places (Version 2) Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6, Revised) Since December 2019, multiple cases of novel coronavirus pneumonia (NCP) have been identified in Wuhan, Hubei. With the spread of the epidemic, such cases have also been found in other parts of China and abroad. As an acute respiratory infectious disease, NCP has been included in class B infectious diseases prescribed in the Law of the People's Republic of China on Prevention and Treatment of Infectious Diseases, and managed as an infectious disease of class A. With a better understanding of the epidemic and accumulation of diagnosis and treatment experience, we now release the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6), which is based on the fifth trial version. I. Etiological Characteristics The novel coronaviruses belong to the β genus. They have envelopes, and the particles are round or oval, often polymorphic, with diameter being 60 to 140 nm. Their genetic characteristics are significantly different from SARS-CoV and MERS-CoV. Current research shows that they share more than 85% homology with bat SARS-like coronaviruses (bat-SL-CoVZC45). When isolated and cultured in vitro, the 2019-nCoV can be found in human respiratory epithelial cells in about 96 hours, however it takes about 6 days for the virus to be found if isolated and cultured in Vero E6 and Huh-7 cell lines. Most of the know-how about the physical and chemical properties of coronavirus comes from the research on SARS-CoV and MERS-CoV. The virus is sensitive to ultraviolet and heat. Exposure to 56°C for 30 minutes and lipid solvents such as ether, 75% ethanol, chlorine-containing disinfectant, peracetic acid, and chloroform can effectively inactivate the virus. Chlorhexidine has not been effective in inactivating the virus. II. Epidemiological Characteristics 1. Source of infection Now, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. 2. Transmission Transmission of the virus happens mainly through respiratory droplets and close contact. There is the possibility of aerosol transmission in a relatively closed environment for a long time exposure to high concentrations of aerosol. 3. Susceptible groups People are generally susceptible. III. Clinical Characteristics 1. Clinical manifestations Based on the current epidemiological investigation, the incubation period is one to 14 days, mostly three to seven days. Main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases. Severe cases mostly developed dyspnea and/or hypoxemia after one week. In severe cases, patients progress rapidly to acute respiratory distress syndrome, septic shock, metabolic acidosis that is difficult to correct, coagulopathy, multiple organ failure and others. It is worth noting that for severe and critically ill patients, their fever could be moderate to low, or even barely noticeable. The patients with mild symptoms did not develop pneumonia but only low fever and mild fatigue. From current situations, most patients have good prognosis and a small number of patients are critically ill. The prognosis for the elderly and patients with chronic underlying diseases is poor. Children’s symptoms are relatively mild. 2. Laboratory tests In the early stages of the disease, peripheral WBC count is normal or decreased and the lymphocyte count decreases. Some patients see an increase in liver enzymes, lactate dehydrogenase (LDH), muscle enzymes and myoglobin. Elevated troponin is seen in some critically ill patients while most patients have elevated C-reactive protein and erythrocyte sedimentation rate and normal procalcitonin. In severe cases, D-dimer increases and peripheral blood lymphocytes progressively decrease. Severe and critically ill patients often have elevated inflammatory factors. Novel coronavirus nucleic acid can be detected in nasopharyngeal swabs, sputum, lower respiratory tract secretions, blood, feces and other specimens. In order to increase the positive rate of nucleic acid detection, it is recommended to take as much sputum as possible, while lower respiratory tract secretions of patients undergoing tracheal intubation should be collected, and the specimens should be submitted for examination as soon as possible after collection. 3. Chest imaging In the early stage, imaging shows multiple small patchy shadows and interstitial changes, apparent in the outer lateral zone of lungs. As the disease progresses, imaging then shows multiple ground glass opacities and infiltration in both lungs. In severe cases, pulmonary consolidation may occur while pleural effusion is rare. IV. Case Definitions 1. Suspect cases Considering both the following epidemiological history and clinical manifestations: 1.1 Epidemiological history 1.1.1 History of travel to or residence in Wuhan and its surrounding areas, or in other communities where cases have been reported within 14 days prior to the onset of the disease; 1.1.2 In contact with novel coronavirus infected people (with positive results for the nucleic acid test) within 14 days prior to the onset of the disease; 1.1.3 In contact with patients who have fever or respiratory symptoms from Wuhan and its surrounding area, or from communities where confirmed cases have been reported within 14 days before the onset of the disease; or 1.1.4 A cluster of cases. 1.2 Clinical manifestations 1.2.1 Fever and/or respiratory symptoms; 1.2.2 The aforementioned imaging characteristics of NCP; 1.2.3 Normal or decreased WBC count and decreased lymphocyte count in the early stage of onset. A suspect case has any of the epidemiological history plus any two clinical manifestations or all three clinical manifestations if there is no clear epidemiological history. 2. Confirmed cases Suspect cases with one of the following etiological evidence: 2.1 Real-time fluorescent RT-PCR indicates positive for new coronavirus nucleic acid; 2.2 Viral gene sequence is highly homologous to known new coronaviruses. V. Clinical Classification 1. Mild cases The clinical symptoms were mild, and there was no sign of pneumonia on imaging. 2. Moderate cases Showing fever and respiratory symptoms with radiological findings of pneumonia. 3. Severe cases Cases meeting any of the following criteria: 3.1 Respiratory distress (≧30 breaths/ min); 3.2 Oxygen saturation≤93% at rest; 3.3 Arterial partial pressure of oxygen (PaO2)/ fraction of inspired oxygen (FiO2) ≦300mmHg (l mmHg=0.133kPa). PaO2/ FiO2 in high-altitude areas (at an altitude of over 1,000 meters above the sea level) shall be corrected by the following formula: PaO2/ FiO2 ✖[Atmospheric pressure (mmHg)/760] Cases with chest imaging that showed obvious lesion progression within 24-48 hours >50% shall be managed as severe cases. 4. Critical cases Cases meeting any of the following criteria: 4.1 Respiratory failure and requiring mechanical ventilation; 4.2 Shock; 4.3 With other organ failure that requires ICU care. VI. Differential Diagnosis 1. The mild manifestations of NCP need to be distinguished from upper respiratory tract infections caused by other viruses. 2. NCP is mainly distinguished from other known viral pneumonia and mycoplasma pneumoniae infections such as influenza virus, adenovirus and respiratory syncytial virus. Especially for suspect cases, methods such as rapid antigen detection and multiplex PCR nucleic acid detection should be adopted as much as possible for detection of common respiratory pathogens. 3. It should also be distinguished from non-infectious diseases such as vasculitis, dermatomyositis and organizing pneumonia. VII. Case Finding and Reporting Health professionals in medical institutions of all types and at all levels, upon discovering suspect cases that meet the definition, should immediately put them in single room for isolation and treatment. If the cases are still considered as suspected after consultation made by hospital experts or attending physicians, it should be reported directly online within 2 hours; samples should be collected for new coronavirus nucleic acid testing and suspect cases should be safely transferred to the designated hospitals immediately. People who have been in close contact with patients who have been confirmed of new coronavirus infection are advised to perform new coronavirus pathogenic testing in a timely manner, even though common respiratory pathogens are tested positive. VIII. Treatment 1. Treatment venue determined by the severity of the disease 1.1 Suspected and confirmed cases should be isolated and treated at designated hospitals with effective isolation, protection and prevention conditions in place. A suspect case should be treated in isolation in a single room. Confirmed cases can be treated in the same room. 1.2 Critical cases should be admitted to ICU as soon as possible. 2. General treatment 2.1 Letting patients rest in bed and strengthening support therapy; ensuring sufficient caloric intake for patients; monitoring their water and electrolyte balance to maintain internal environment stability; closely monitoring vital signs and oxygen saturation. 2.2 According to patients’ conditions, monitoring blood routine result, urine routine result, c-reactive protein (CRP), biochemical indicators (liver enzyme, myocardial enzyme, renal function etc.), coagulation function, arterial blood gas analysis, chest imaging and cytokines detection if necessary. 2.3 Timely providing effective oxygen therapy, including nasal catheter and mask oxygenation, and if necessary, nasal high-flow oxygen therapy. 2.4 Antiviral therapy: Hospitals can try Alpha-interferon (5 million U or equivalent dose each time for adults, adding 2ml of sterilized water, atomization inhalation twice daily), lopinavir/ritonavir (200mg/50mg per pill for adults, two pills each time, twice daily, no longer than 10 days), Ribavirin (suggested to be used jointly with interferon or lopinavir/ritonavir, 500mg each time for adults, twice or three times of intravenous injection daily, no longer than 10 days), chloroquine phosphate (500mg for adults, twice daily, no longer than 10 days), Arbidol (200mg for adults, three times daily, no longer than 10 days). Be aware of such adverse reactions as lopinavir/ritonavir-related diarrhea, nausea, vomiting, liver damage, and pay attention to interactions with other drugs. Further evaluate the efficacy of those drugs currently being used. Do not recommend using three or more antiviral drugs at the same time; if an intolerable toxic side effect occurs, the respective drug should be discontinued. 2.5 Antibiotic drug treatment: Blind or inappropriate use of antibiotic drugs should be avoided, especially in combination with broad-spectrum antibiotics. 3. Treatment of severe and critical cases 3.1 Treatment principle: On the basis of symptomatic treatment, complications should be proactively prevented, underlying diseases should be treated, secondary infections also be prevented, and organ function support should be provided timely. 3.2 Respiratory support: 3.2.1 Oxygen therapy: Patients with severe symptoms should receive nasal cannulas or masks for oxygen inhalation and timely assessment of respiratory distress and/or hypoxemia should be performed. 3.2.2 High-flow nasal-catheter oxygenation or noninvasive mechanical ventilation: When respiratory distress and/or hypoxemia of the patient cannot be alleviated after receiving standard oxygen therapy, high-flow nasal cannula oxygen therapy or non- invasive ventilation can be considered. If conditions do not improve or even get worse within a short time (1-2 hours), tracheal intubation and invasive mechanical ventilation should be used in a timely manner. 3.2.3 Invasive mechanical ventilation: Lung protective ventilation strategy, namely low tidal volume (4-8ml/kg of ideal body weight) and low inspiratory pressure (platform pressure <30cmH20) should be used to perform mechanical ventilation to reduce ventilator-related lung injury. There are many cases of human-machine asynchronization, therefore sedation and muscle relaxants should be used in a timely manner. 3.2.4 Rescue therapy: Pulmonary re-tensioning is recommended for patients with severe ARDS. With sufficient human resources, prone position ventilation should be performed for more than 12 hours per day. If the outcome of prone position ventilation is poor, extracorporeal membrane oxygenation (ECMO) should be considered as soon as possible. 3.3 Circulatory support: On the basis of adequate fluid resuscitation, hospitals should improve microcirculation, use vasoactive drugs and perform hemodynamic monitoring when necessary. 3.4 Rehabilitation plasma treatment: It is suitable for patients with rapid disease progression, severe and critically ill patients. Usage and dosage should refer to Clinical Treatment Plan for Convalescent Patients with NCP during Recovery Phase (first trial version). 3.5 Other therapeutic measures For patients with progressive deterioration of oxygenation indicators, rapid progress in imaging and excessive activation of the body's inflammatory response, glucocorticoids can be used in a short period of time (three to five days). It is recommended that dose should not exceed the equivalent of methylprednisolone 1-2 mg/kg/day. Note that a larger dose of glucocorticoid will delay the removal of coronavirus due to immunosuppressive effects. Xuebijing 100ml/time can be administered intravenously twice a day. Intestinal microecological regulators can be used to maintain intestinal microecological balance and prevent secondary bacterial infections. For critically ill patients with high inflammatory reactions, extracorporeal blood purification technology can be considered when conditions permit, such as plasma exchange, adsorption, perfusion, blood/plasma filtration. Patients often suffer from anxiety and fear and they should be supported by psychological counseling. 4. Traditional Chinese Medicine treatment This disease belongs to the category of plague in traditional Chinese medicine (TCM), caused by the epidemic pathogenic factors. According to the different local climate characteristic and individual state of illness and physical conditions, the following treatment Protocol may vary. The use of over-pharmacopoeia doses should be directed by a physician. 4.1 During medical observation Clinical manifestation 1: fatigue and gastrointestinal discomfort Recommended Chinese patent medicine: Huoxiang Zhengqi capsules (pills, liquid, or oral solution) Clinical manifestation 2: fatigue and fever Recommended Chinese patent medicine: Jinhua Qinggan granules, Lianhua Qingwen capsules (granules), Shufeng Jiedu capsules (granules), Fangfeng Tongsheng pills (granules) 4.2 During clinical treatment (confirmed cases) 4.2.1 Lung cleansing & detoxifying decoction Scope of application: It is suitable for light, moderate and severe patients, and can be used reasonably in combination with the actual situation of patients in the treatment of critically ill patients. Recommended prescription: Ephedra 9g, Zhigancao 6g, Almond 9g, Gypsum 15- 30g (fried first), Guizhi 9g, Zixie 9g, Zhuling 9g, Baizhu 9g, Zhiling 15g, Bupleurum 16g, Scutellaria baicalensis 6g, and Pinellia 9g , Ginger 9g, aster 9g, winter flower 9g, shoot dry 9g, asarum 6g, yam 12g, coriander fruit 6g, tangerine peel 6g, aquilegia 9g. Suggested use: Traditional Chinese medicine decoction pieces for decocting in water. One dose per day, twice in the morning and evening (forty minutes after a meal), take with warm water, and three doses a course. If conditions permit, the patient can take half a bowl of rice soup each time after taking the medicine, and can take up to one bowl if the patient has a dry tongue and is deficient in bodily fluids. (Note: If the patient does not have a fever, the amount of gypsum should be little. If having a fever or strong heat, the amount of gypsum can be increased). If the symptoms improve but do not fully recover, then take the second course of treatment. If the patient has special conditions or other underlying diseases, the prescription of the second course of treatment can be modified based on the actual situation and the medicine should be discontinued when the symptoms disappear. Source of prescription: Notice on Recommending the Use of ‘Lung cleansing & detoxifying decoction’ in Treatment of NCP by Integrated Traditional Chinese and Western Medicine by the Office of the State Administration of Traditional Chinese Medicine & the General Office of the National Health Commission. (2022 No.22) 4.2.2 Mild cases 4.2.2.1 Cold dampness and stagnation lung syndrome Clinical manifestations: fever, fatigue, sore body, cough, expectoration, chest tightness, suffocation, loss of appetite, nausea, vomiting, sticky stools. Tongue has thin fat tooth mark or is faint red, and the coating is white thick rot or white greasy and the pulse is moisten or slippery. Recommended prescription: Raw ephedra 6g, raw gypsum 15g, almond 9g, loquat 15g, gardenia 15g, Guanzhong 9g, Dilong 15g, Xu Changqing 15g, Huoxiang 15g, Peilan 9g, Cangzhu 15g, Yunling 45g, Atractylodes 30g, Jiao Sanxian 9g each , Magnolia officinalis 15g, betel coconut 9g, yarrow fruit 9g, ginger 15g. Suggested use: one dose daily, boiled with 600ml water, take it three times at morning, noon and evening before meal. 4.2.2.2 Dampness and heat-accumulation lung syndrome Clinical manifestations: low or no fever, slight chills, fatigue, heavy head and body, muscle soreness, dry cough, low phlegm, sore throat, dry mouth, do not want to drink more, or accompanied by chest tightness, no sweat or sweating, Or vomiting and loss of appetite, diarrhea or sticky stool. The tongue is reddish, and the coating is white, thick and greasy or thin yellow, and the pulse is slippery or sloppy. Recommended prescription: Betel nut 10g, apple 10g, Magnolia 10g, Zhimu 10g, scutellaria baicalensis 10g, Bupleurum 10g, red peony 10g, forsythia 15g, artemisia annua 10g (decocted later), 10g of green leaves, 10g of green leaves, 5g of raw licorice. Suggested use: one dose daily, boiled with 400ml water, take it twice at morning and evening. 4.2.3 Moderate cases 4.2.3.1 Dampness and stagnation lung syndrome Clinical manifestations: fever, low cough and sputum, or yellow sputum, suffocation, shortness of breath, bloating, and constipation. The tongue is dark red and fat; the coating is greasy or yellow and the pulse is slippery or stringy. Recommended prescription: raw ephedra 6g, bitter almond 15g, raw gypsum 30g, raw coix seed 30g, grass root 10g, patchouli 15g, artemisia annua 12g, Polygonum cuspidatum 20g, verbena 30g, dried reed root 30g, gardenia 15g 15g of orange red, 10g of raw licorice. Suggested use: one dose daily, boiled with 400ml water, take it twice at morning and evening. 4.2.3.2 Cold dampness lung syndrome Clinical manifestations: low fever, low body temperature, or no heat, dry cough, low sputum, fatigue, chest tightness, nausea, or nausea. The tongue is pale or red, and the coating is white or greasy, and the veins are pulsating. Recommended prescription: Atractylodes lancea 15g, Chenpi 10g, Magnolia 10g, Aquilegia 10g, grass fruit 6g, raw ephedra 6g, Zhihuo 10g, ginger 10g, betel nut 10g. Suggested use: one dose daily, boiled with 400ml water, take it twice at morning and evening. 4.2.4 Severe cases 4.2.4.1 Plague poison and lung-closing syndrome Clinical manifestations: fever, flushing, cough, yellowish phlegm, or blood in sputum, wheezing, shortness of breath, tiredness, fatigue, dryness and stickiness, nausea, food loss, poor stool, and short urination. Red tongue, yellow greasy coating, slippery pulses. Recommended prescription: Raw ephedra 6g, almond 9g, raw gypsum 15g, licorice 3g, fragrant fragrant 10g (back), Magnolia 10g, atractylodes 15g, grass fruit 10g, pinellia 9g, Poria 15g, raw rhubarb 5g (back) 10g, gardenia 10g, red peony 10g. Suggested use: one or two doses daily, boiled with 100-200ml water, take it 2-4 times, oral or nasal feeding. 4.2.4.2 Syndrome of flaring heat in qifen and yingfen Clinical manifestations: Hot fever, thirst, shortness of breath, shortness of breath, blurred vision, or spotted rash, or vomiting blood, bleeding, or convulsions in the limbs. Tongue ridges have few or no moss, and the pulse sinks finely, or floats large and counts. Recommended prescription: 30-60g gypsum (fried first), 30g of Zhimu, 30- 60g of raw land, 30g of buffalo horn (fried first), 30g of red sage, 30g of black ginseng, 15g of forsythia, 15g of paeonia, 6g of peony 12g, gardenia 15g, raw licorice 6g. Suggested use: 1 dose per day, decoction, first decoct gypsum and buffalo horn, then apply other pieces, 100ml-200ml each time, 2-4 times a day, orally or nasally. Recommended Chinese patent medicines: Xiyanping injection, Xuebijing injection, Reduning injection, Tanreqing injection, Xingnaojing injection. Drugs with similar efficacy can be selected according to individual conditions, or can be used in combination according to clinical symptoms. Traditional Chinese medicine injection can be used in combination with traditional Chinese medicine decoction. 4.2.5 Critical cases (syndrome of inner blocking causing collapse) Clinical manifestations: dyspnea, dyspnea, asthma or need mechanical ventilation, fainting, irritability, cold sweating, dark purple tongue, thick or dry moss, large floating roots. Recommended prescription: 15g of ginseng, 10g of Heishun tablets (decoct first), 15g of dogwood, delivered with Suhexiang Pill or Angong Niuhuang Pill. Recommended Chinese patent medicines: Xuebijing injection, Reduning injection, Tanreqing injection, Xingnaojing injection, Shenfu injection, Shengmai injection, Shenmai injection. Drugs with similar efficacy can be selected according to individual conditions, or can be used in combination according to clinical symptoms. Traditional Chinese medicine injection can be used in combination with traditional Chinese medicine decoction. Note: Recommended usage of Chinese medicine injections for severe and critical cases The use of traditional Chinese medicine injections follows the principle of starting from a small dose and gradually adjusting the dosage according to the instructions of the drug. The recommended usage is as follows: Viral infection or combined mild bacterial infection: 0.9% sodium chloride injection 250ml plus Xiyanping injection 100mg bid, or 0.9% sodium chloride injection 250ml heated Duning injection 20ml, or 0.9% sodium chloride injection 250ml plus Tanreqing injection 40ml bid. High fever with disturbance of consciousness: 250ml of 0.9% sodium chloride injection and 20ml bid of Xingnaojing injection. Systemic inflammatory response syndrome or/and multiple organ failure: 250ml of 0.9% sodium chloride injection and 100ml of Xuebijing injection. Immunosuppression: 250ml of 0.9% sodium chloride injection and 100ml bid of Shenmai injection. Shock: 250ml of 0.9% sodium chloride injection plus 100ml bid of Shenfu injection. 4.2.6 Convalescent period 4.2.6.1 Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g Suggested use: 1 dose per day, boiled with 400ml of water, twice a day at morning and evening. 4.2.6.2 Qi and Yin deficiency syndrome Clinical manifestations: Fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice. Suggested use: 1 dose per day, boiled with 400ml of water, twice a day at morning and evening. IX. Isolation Removal and After-discharge Notice 1. Criteria for isolation removal and discharge 1) Body temperature is back to normal for more than three days; 2) Respiratory symptoms improve obviously; 3) Pulmonary imaging shows obvious absorption of inflammation, 4) Nuclei acid tests negative for respiratory tract pathogen twice consecutively (sampling interval being at least one day). Those who meet the above conditions can be discharged from isolation. 2. After-discharge notice 2.1 The designated hospitals should contact the primary healthcare facilities where the patients live and share patients’ medical record, to send the information of the discharged patients to the community committee and primary healthcare facility where the patients reside. 2.2. After discharge, due to their low immune function during the recovery phase, the patients have the risks of infection with other pathogens; it is recommended for patients to monitor their own health status for 14 days, wear a mask, live in well- ventilated single room if possible, reduce close contact with family members, separate dinning, practice hand hygiene and avoid going out. 2.3 It is recommended for the patients to return to the hospitals for follow-up and re- visit in two and four weeks after discharge. X. Patients Transportation Principles Patients should be transported in accordance with the Work Protocol for Transfer of the Novel Coronavirus Pneumonia Patients (Trial Version) issued by the National Health Commission. XI. Nosocomial Infection Prevention and Control Measures to prevent and control nosocomial infection should be implemented in accordance with the requirements of the Technical Guidelines for the Prevention and Control of Infection by the Novel Coronavirus in Medical Institutions (First Edition) and the Guidelines on the Usage of Common Medical Protective Equipment against Novel Coronavirus Infection (Trial Version) formulated by the National Health Commission. The General Office of National Health Commission Office of State TCM Administration Printed and distributed on February 18, 2020 (Issued by China CDC) Contents A. Prevention and control guidelines for special groups of people A1. Prevention and control guidelines for the elderly A2. Prevention and control guidelines for children A3. Prevention and control guidelines for students B. Prevention and control guidelines for specific settings B1. Prevention and control guidelines for kindergartens/schools B2. Prevention and control guidelines for nursing homes B3. Prevention and control guidelines for workplaces B4. Prevention and control guidelines for public transportation B5. Prevention and control guidelines for public places B6. Prevention and control guidelines for home quarantine C. Expert advice Expert advice on Chinese and Western combined medicine treatment for home-based patients in the community (Edition 1) A. Prevention and control guidelines for special groups of people A1. Prevention and control guidelines for special groups of people: the elderly 1. Ensure that the elderly are aware of personal protection measures against nCoV infection, hand hygiene requirements, healthy habits and avoiding sharing personal items, as well as paying attention to ventilation and implementing disinfection measures. Encourage the elderly to make washing hands regularly their healthy habit. 2. The following measures should be taken if the older person has fever, cough, sore throat, chest stuffiness, breathing difficulty, fatigue, nausea, vomiting, diarrhea, conjunctivitis, muscle pain or other suspect symptoms: (1) Self isolation to avoid close contact with others. (2) Health assessment is conducted by health care workers who decide if the patient should be transferred to a healthcare facility for medical care. During the transportation, the patient should wear surgical masks and avoid riding public transportation. (3) People in unprotected close contact with the person with suspect symptoms should be registered immediately and put under medical observation. (4) Avoid unnecessary mass gatherings such as parties or dinners; avoid group dinner. (5) If the older patient with suspect symptoms is confirmed to be a case with nCoV pneumonia, the close contacts should be put under medical observation for 14 days. After the patient is evacuated (eg. Hospitalized or dead), timely terminal disinfection should be conducted in the residence, which should be performed or guided by the local CDC staff or a qualified third party. It is advised that the residence should not be used before disinfection. A2. Prevention and control guidelines for special groups of people: children 1. Avoid getting into crowds of people; avoid mass gathering. 2. Wear masks when going out and remind the parents and grandparents to wear masks. 3. Keep regular daily schedule with balanced diet. Wash hands before meals and after toilet. Do physical exercises with parents at home. 4. Foster good respiratory etiquette including covering nose and mouth with tissue or elbow when sneezing or coughing. 5. Cooperate with parents in seeking medical care timely if having fever or sick. A3. Prevention and control guidelines for special groups of people: students 1. During winter vacation (1) Students having lived or travel to outbreak areas (eg Wuhan) should be under medical observation at home or in a designated place for 14 days after leaving the outbreak area. (2) Students in all areas should stay at home as much as possible to minimize visits to relatives and friends, parties, group dinners and mass gatherings in public places, in particular poorly ventilated places. (3) Students are advised to monitor their health status daily and report the result to the designated person in the community or school following relevant requirements. (4) Upon the completion of the winter vacation, students without any suspect symptoms can return to school as usual. Students with suspect symptoms should report directly or through their guardians to the school, seek medical care timely and return to school after recovery. 2. On way to school (1) Wear surgical masks or N95 masks all the time when taking public transportation. (2) Practise hand hygiene and minimize contacts with common surfaces or articles in public transportation. (3) Monitor health status during travel. Take body temperature if you feel having a fever. (4) Be cautious about the health status of passengers around you and avoid close contacts with people with suspect symptoms. (5) If you develop suspect symptoms during the travel, you should put on surgical masks or N95 masks, avoid as much as possible contacts with others and seek medical care based on your medical condition. (6) When you go to a healthcare facility for medical care during the travel, you should share with the doctor your travel history to the outbreak area and cooperate with the doctor in relevant investigation. (7) Keep good record of your travel documents and tickets in order to cooperate in any possible close contact investigation. B. Prevention and control guidelines for specific settings B1. Prevention and control guidelines for specific settings: kindergartens/schools 1. Students who have lived in or traveled to epidemic areas (such as Wuhan) before returning to school are advised to have home quarantine for 14 days before returning to school. 2. After returning to school, students should monitor their body temperature and health status daily, avoid unnecessary going out as much as possible and avoid contact with other people. 3. Students in close contact with other teachers and students should wear surgical masks or N95 masks correctly and minimize the range of their movement. 4. Schools should closely monitor the health status of students by measuring their body temperature twice a day and making a good record of absences, early departures and leaves, and report any suspect symptoms to the outbreak manager immediately. Schools should cooperate with health care facilities in close contact management and disinfection. 5. Schools should avoid organizing mass gathering activities as much as possible. Ventilation should be enhanced, and hand sanitizers should be made available in classrooms, dormitories, libraries, activity centers, canteens, auditorium, teachers' offices, bathroom and other activity areas. 6. Schools should provide online teaching or catch-up teaching for students who have missed classes and arrange make-up examinations for the students who have missed the regular exam, which should not be recorded in the archive. B2. Prevention and control guidelines for specific settings: nursing homes It is recommended that nursing homes implement closed-off management during outbreaks. In principle, visitors are not allowed to get in and the elderly inhabitants are not allowed to go out; no new admission of the elderly to the nursing home; those who have gone out should be under close monitoring after return. 1. Daily preventive measures (1) Ensure the staff and the older people under care are aware of the relevant information, avoid sharing personal items, pay attention to ventilation, and implement disinfection measures. Set up health records for the older people and staff and check and record health status every morning. (2) Staff developing suspect symptoms should stop duty immediately and seek medical screening. Only those who have been excluded of with infectious diseases including nCoV infection can resume duty. (3) Set up visitor registration system. Visitors with suspect symptoms of nCoV infection should be rejected for visit. All visitors should wear surgical masks. (4) Keep good ventilation of the room. Keep the window open for at least 30 minutes in the morning and in the afternoon. In case opening windows are not feasible, mechanical ventilation should be installed. In winter windows should be opened with caution to avoid catching cold due to the difference in indoor and outdoor temperature. (5) Encourage the elderly to wash hands regularly and keep the environment tidy and clean. (6) Prepare isolation rooms for possible patients with suspect symptoms in the future. older people with symptoms should be isolated timely to prevent the spread of infection to others. 2. When an older person has suspect symptoms: If an older person in the nursing home develops suspect symptoms, the older person should be isolated timely in a single room, assessed by health professional who shall decide if the patient should be transferred to a healthcare facility for medical care. Visits should be suspended. B3. Prevention and control guidelines for specific settings: workplaces 1. Workers should self-monitor their health status. Stop going to work if any of the nCoV infection suspect symptoms (including fever, cough, sore throat, chest stuffiness, breathing difficulty, fatigue, nausea, vomiting, diarrhea, conjunctivitis, muscle pain, etc.) develops. 2. Persons with suspect symptoms of nCoV infection should be requested by staff to leave. 3. Commonly used or touched articles or sites should be cleaned and disinfected regularly. 4. Keep good ventilation in workplaces. Ensure the AC system or exhaust fan in operation; clean the AC filter regularly; open windows for better ventilation. 5. Make hand sanitizer available all the time in the toilet room; ensure water supply such as the running water in good operation. 6. Keep good environmental hygiene and dispose of garbage timely. B4. Prevention and control guidelines for specific settings: public transportation (including aircrafts, public buses, subways, trains etc.) 1. Public transportation workers in outbreak areas should wear surgical masks or N95 masks and monitor health status on a daily basis. 2. Public transportation is advised to be equipped with thermometer, masks, etc. 3. Increase the frequency of cleaning and disinfection of public transportation; keep good record of cleaning and disinfection and mark with signs. 4. Keep good ventilation in public transportation. 5. Keep good hygiene in stations and carriages and dispose of garbage timely. 6. Drivers and conductors should work in shifts with a schedule that allows them enough rest. B5. Prevention and control guidelines for specific settings: public places This Guideline is applicable to shopping malls, restaurants, cinemas, KTVs, Internet cafes, public baths, gymnasiums, exhibition halls, railway stations, subway stations, airports, bus stations and other public places. 1. Workers in public places should self-monitor their health status and do not come to work sick if they have suspect symptoms of nCoV infection. 2. Persons with suspect symptoms of nCoV infection should be requested by staff to leave. 3. Commonly used or touched articles or sites should be cleaned and disinfected regularly. 4. Keep good ventilation in public places. Ensure the AC system or exhaust fan in operation; clean the AC filter regularly; open windows for better ventilation. 5. Make hand sanitizer available all the time in the toilet room; ensure water supply such as the running water in good operation. 6. Keep good environmental hygiene and dispose of garbage timely. 7. In epidemic areas, the public should minimize access to public places, especially to areas with high population density and poor ventilation. B6. Prevention and control guidelines for specific settings: home quarantine 1. Arrangement of living space (1) Persons with suspect symptoms should live in well ventilated single rooms and decline all visits. (2) Family members should live in different rooms; if not feasible, they should keep at least 1 meter apart from each other and sleep in separate beds. Persons with suspect symptoms should reduce your movement, restrict your own living space, and ensure good ventilation in shared spaces (such as kitchens and bathrooms) (keep windows sustainedly open). 2. Arrangement of the carer Ideally keep one family member as the fixed carer who should be in good health and free from chronic diseases. 3. Prevention of spread When a family member stays with the person with suspect symptoms in the same room, both should wear well and tightly fitted surgical masks. Keep good hand hygiene; avoid direct contact with body excreta; avoid any contact with anything that may lead to infections through indirect exposure. 4. Management of contaminated stuff Used gloves, tissues, masks and other wastes should be put into the designated garbage bag marked as contaminated before it is disposed of. 5. Stop home quarantine and seek medical care immediately if having any of the following symptoms: (1) Breathing difficulty (including worsened chest stuffiness and short of breath after movement);. (2) Problems with consciousness (including drowsiness, deliriousness, disorientation, etc); (3) Diarrhea. (4) Body temperature over 39C. (5) Suspect symptoms of infection with nCoV among other family members. C. Expert advice on Chinese and Western combined medicine treatment for home-based patients in the community (Edition 1) Data available show that since the novel coronavirus pneumonia outbreak in Wuhan, Hubei Province in December 2019, the major of cases are mild cases. Late winter and early spring is also the peak time for common cold and flu. As a result, fever clinics and inpatient departments of hospitals are crowded with patients and visitors. Some febrile patients may choose home quarantine because of concerns about the risks of cross infection. This Advice is developed to provide guidance on home quarantine of febrile patients in accordance with the Protocol of Diagnosis and Treatment of nCoV Pneumonia (Version 4), Protocol of Prevention and Control of nCoV Pneumonia (Version 3) and Protocol of Diagnosis and Treatment of Flu (2019). C1. Advice on screening of febrile patients for home quarantine In winter and spring, infectious respiratory diseases are common. Common cold, flu and nCoV pneumonia all can lead to fever, but their symptoms are different. For instance, common cold is manifested by upper respiratory tract symptoms such as sneezing, running nose and throat discomfort with mild general symptoms without fever or very brief fever. Symptoms of influenza include high fever, more severe systemic symptoms, chills, headache, general pains, blocked nose, running nose, dry cough, chest pain, nausea, loss of appetite, etc. nCoV pneumonia is characterized by fever, fatigue and dry cough; a few patients may have symptoms like nasal blockage, running nose and diarrhea. With onset of symptoms such as fever and cough, home quarantine is advised for the following scenarios: 1. Symptoms are mild with body temperature below 38C, no obvious short of breath, chest stuffiness, breathing difficulty; vital signs such as breathing, blood pressure and heart rate are stable. 2. Patients have no major underlying respiratory or cardiovascular diseases or severe obesity. C2. Advice on medical management of febrile patients under home quarantine 1. Rest; balanced diet; avoid greasy food; 2. Drink warm water and avoid cold water to comfort the digestive system; 3. Avoid inappropriate use of antibiotics; 4. Wear masks correctly; eat meal separately from other family members; keep 1.5 meters away from other family members. 5. Patients with chill may use traditional Chinese patent medicines that are antipyretic and anti-cold. 6. Patients with chill, fever, muscle pain and cough may use traditional Chinese patent medicines that can clear heat and toxics and stop coughing. 7. Patients with fatigue, nausea, poor appetite and diarrhea may use traditional Chinese patent medicines that can relieve moisture. 8. Patients with fever and sore throat may use traditional Chinese patent medicines that can clear heat and toxics and comfort throat. 9. Patients with fever and inhibited defecation may add drugs that can relax bowel and discharge heat. 10. If body temperature is over 38.5C, physical cooling measures can be applied such as wet towels or ice bags. It is advised that patients take oral antipyretic analgesics or medicines that can clear heat and toxics. Refer to the Protocol for Diagnosis and Treatment of nCoV Pneumonia (version 4) for specific recommended medicines. C3. Home-based prevention and control measures for febrile patients 1. The patient is advised to be under home quarantine for 7 days. 2. Maintain cleanliness and good ventilation in the living environment. Ventilate the room for half an hour in the morning, at noon and in the evening while keep warm when doing so. 3. Know how to wear masks correctly; have good respiratory etiquette (covering nose and mouth with elbow instead of hands when coughing or sneezing); wash hands frequently (not touching nose, mouth, eyes with unwashed hand); cover the toilet before flushing. 4. Avoid gatherings and group dinners and minimize the length of stay in crowded places. 5. Patients with symptoms such as fever or cough should be aware of ways of self-protection such as isolation in single rooms; if not feasible, patients should keep at least 1.5 meters away from other family members; keep the door closed all the time to avoid cross-ventilation among different rooms; avoid using central air-conditioning. 6. All should wear masks on the way to a hospital for seeking medical care. 7. Masks used by febrile patients should be sealed in a storage bag before being disposed of into a garbage bin. C4. Monitoring of symptoms of febrile patients under home quarantine 1. Closely monitor body temperature at least twice a day. 2. Watch for chest stuffiness, short of breath, rapid breathing, increased heart rate etc. 3. Watch if intestinal tract symptoms like diarrhea or vomiting are worsening. C5. Advice on the management of abnormal symptoms during home quarantine 1. Seek medical care in a designated hospital or a fever clinic if having the following: (1) Body temperature high for 2 consecutive hours; (2) Chest stuffiness or short of breath. 2. If breath frequency is or faster than 30 times/minute with breathing difficulty and cyanosis of lips, call 120 to get emergency care workers to transfer the patient to the designated hospital or fever clinic for treatment. The advice is to be revised and improved based on clinical evidences. It is advised to use it based on the local context. Saatja: 林 昀 <[email protected]> Saadetud: 24.02.2020 10:03 Adressaat: <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; SM Info <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; Kancelaria <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]> Teema: Relevant technical guidelines for COVID-2019 (Updated) Manused: Protocols 20200223.zip Dear colleagues from Central and Eastern European Countries, Please find attached the updated relevant technical guidelines adopted in China for the current COVID-2019 outbreak, as attached. Thank you for your kindness. Best wishes, LIN Yun (Ms.) European and American Affairs Department of International Cooperation National Health Commission, China Tel: +86 10 6879 2502 Fax: +86 10 6879 2285
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel